ZYDUSLIFE

###

| Extinguishes 87.3 Lakh Shares Under Buyback Zydus Lifesciences has extinguished **87.3 lakh equity shares** bought back at **₹1,260 per share**, completing its fully subscribed buyback program worth approximately **₹1,100 crore**. Following the extinguishment, the company's outstanding share capital has reduced to **99.75 crore shares**, while promoter holding increased marginally to **75.01%**. The reduction in share count is expected to improve earnings per share (EPS) and enhance shareholder value over time. **Impact:** Share buyback and extinguishment are generally viewed positively as they improve capital efficiency, support EPS growth, and reflect management confidence in the business. ------------------ ### | FY26 Revenue Crosses ₹5,000 Crore, PAT Tops ₹1,000 Crore Ajanta Pharma reported a strong FY26 performance with **revenue rising 17% YoY to ₹5,453 crore** and **PAT increasing 15% YoY to ₹1,056 crore**. Adjusted EBITDA stood at **₹1,498 crore**, with a healthy **27% EBITDA margin**. Growth was driven by strong performance across key businesses, with **US Generics revenue surging 49%**, while the India business outperformed the IPM growth rate. **Impact:** Strong earnings growth, healthy profitability, and broad-based business momentum reinforce the company's long-term growth outlook.